BioWorld

Jan. 17, 2012

Record Year for Royalty Deals Builds Optimism for 2012

Not everyone is upset about the turmoil in the equity markets. Last year was a record year for the sale of royalty streams and other structured product deals, in large part because of the lack of other options for biotechs. Read More

Too Many Trials Still Published At a Glacial Pace, or Not at All

Supposedly, academia's battle cry is "publish or perish." So why are so many clinical trials going unpublished? Read More

Week in Review

Word on the Street

Week in Washington

Biotech Restructurings, Expansions, Scale-Backs, Bankruptcies: Jan. 1 - Dec. 31, 2011

Biotech Lawsuits: Jan. 1 - Dec. 31, 2011

Money Raised By Biotech In 2012 Vs. 2011

Money Raised By Biotech: Jan. 1 - 13, 2012

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for June 9, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

BioWorld Science

Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.

Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors

BioWorld Science

Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...